Pulmonary toxicity studies of bleomycin tested before and after its expiration date.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
S T Crooke
Publications and source records attributed to S T Crooke.
A comparison of the molecular pharmacology of gold and platinum complexes.
Auranofin and cisplatinum have antiarthritic, and antineoplastic activities respectively. Because of the chemical and biological similarities of the two compounds and the extensive studies on molecular pharmacology of cisplatinum, the information about the molecular and pharmacologic effects of these agents is presented and compared. Gold and platinum complexes both can exist in several oxidation states and form coordinate complexes of varying geometry and complexity. Gold complexes interact with bases and nucleosides but relatively little is known about their interaction with polynucleotides. Extrapolating from an understanding of the interactions of platinum complexes with polynucleotides, a number of proposals for additional research on gold complexes are presented. Substantially more information is available concerning the interactions of gold complexes and various proteins. The effects of gold complexes on intracellular macromolecules and their synthesis are poorly understood and should be studied using systems employed to study platinum analogues. It is suggested that 2 dimensional gel electrophoresis of various cellular proteins be employed to determine to which intracellular protein gold complexes bind.
Animals↗
Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report.
Intravesical mitomycin C therapy was administered to 63 patients with noninvasive bladder carcinoma in a phase I-II study. Doses ranged from 20 to 60 mg once a week for 8 weeks. The overall response rate was 67% including a complete remission rate of 45%. The median duration of complete remission for the two lowest dose groups was > 14 months, with a range of 1-36+ months. Followup is not yet adequate to determine the median duration of complete remission for the higher dose groups. No bone marrow suppression or other systemic toxic effects were noted. Adverse effects were localized and occurred infrequently. No mitomycin C was detected in serial serum samples after intravesical instillation.
Absorption↗
Pharmacokinetics of tallysomycin and bleomycin in the beagle dog.
The pharmacokinetics of tallysomycin, a third-generation bleomycin analog, and bleomycin have been determined and compared in the beagle dog. Both compounds exhibited biphasic plasma elimination characteristics and were extensively absorbed after in injection. The elimination half-lives of tallysomycin after iv and im administration were 1.51 +/- 0.41 hours and 2.40 +/- 0.667 hours respectively. These values were longer than the comparable iv (1.01 +/- 0.19 hours) and im (1.12 +/- 0.39 hours) elimination half-lives for bleomycin. The volume of distribution in the central compartment after iv administration was 0.111 +/- 0.039 liter/kg for tallysomycin and 0.125 +/- 0.0723 liter/kg for bleomycin. The total apparent volumes of distribution were 0.706 +/- 0.255 liter/kg and 0.388 +/- 0.245 liter/kg for tallysomycin and bleomycin respectively after iv injection. These values were significantly different (P less than 0.05). Total urinary recovery in 24 hours for tallysomycin was significantly (P less than 0.05) less than that for bleomycin after both iv and im injections. These observed differences in pharmacokinetic behavior may, in part, account for differences in in vivo antitumor activities and toxic effects which have been reported for these drugs.
Animals↗
A radioimmunoassay for tallysomycin.
Antibodies were raised against a new antineoplastic agent, tallysomycin, for use in a radioimmunoassay. The assay was sensitive to 2.5 ng of tallysomycin, had a coefficient of variation of 10.5% at 50 ng/ml, and was highly specific for tallysomycin A. The antibody exhibited reduced cross-reactivity with closely related tallysomycin analogs and little or no immunoreactivity with other antitumor antibiotics including bleomycin and phleomycin. Increased immunoreactivity occurred following copper chelation of tallysomycin B as compared with the non-chelated forms, thus indicating possible conformational alterations upon metal binding.
Antibiotics, Antineoplastic↗